An incredibly cost effective way of finding a chemical starting point

Many customers engage Cresset Discovery Services (CDS) to find a chemical starting point for their project. The input could be a competitor compound, a peptide, or a compound that is unsuitable for development for toxicity or patent reasons. Cresset computational methods are an extremely cost effective way of identifying promising candidate compounds.

Identifying a patentable chemical starting point

A pharmaceutical company was working on a particular target, but the only activity they had found was from a competitor compound. They engaged CDS to find an alternative chemical starting point for their project.

The first step was to generate a binding hypothesis for the competitor compound. This was used as input to a virtual screen in order to identify other compounds with a strong likelihood of having similar activity.

This short and efficient project resulted in a chemical starting point for the customer’s project. The final chosen compound was highly active, was different to the competitor compound and was patentable.

Virtual screening to find different chemotypes

As part of a longer ongoing contractual agreement, a customer purchased flexible service days from CDS and used them on this project over a 12 month period.

The customer was working on a novel ion channel target and they knew of two competitor compounds. CDS aligned the compounds and generated a number of alternative alignment hypotheses. We then carried out a virtual screen on the most diverse of the permutations, leading to 30 different chemotypes, which the customer was able to pursue. This resulted in a promising, patentable chemical starting point for their project.

“Our methods are an incredibly cost effective way to identify promising candidate compounds. For less than $25k for the actual computational chemistry work, plus the same again for the procurement and initial testing, our client had a promising, patentable chemical starting point for their project.”
Dr Martin Slater, Director of Cresset Discovery Services

Identifying drug-like chemotypes from a peptide starting point

Another customer had identified a series of peptides that block the aggregation of β-amyloid. They engaged Cresset to identify drug-like chemotypes to mimic this activity. See the full case study: A novel series of non-peptide small molecules for protein-protein interactions.


Contact us to find out how we can help you find a starting point for your project.